[
  {
    "ts": "2025-10-20T12:37:00+00:00",
    "headline": "Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch",
    "summary": "Citius Oncology, Inc. (\"Citius Oncology\") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. (\"Citius Pharma\") (Nasdaq: CTXR), today announced it has entered into a distribution services agreement with McKesson Corporation (NYSE: MCK), one of the largest pharmaceutical distributors and healthcare services companies in North America. Under the agreement, McKesson will serve as an authorized distributor of record for LYMPHIR (denileukin diftitox-cxdl), a novel immunoth",
    "url": "https://finance.yahoo.com/news/citius-oncology-signs-u-distribution-123700294.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "bc02b0fb-bba6-3168-abf9-70533d8d3a66",
      "content": {
        "id": "bc02b0fb-bba6-3168-abf9-70533d8d3a66",
        "contentType": "STORY",
        "title": "Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch",
        "description": "",
        "summary": "Citius Oncology, Inc. (\"Citius Oncology\") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. (\"Citius Pharma\") (Nasdaq: CTXR), today announced it has entered into a distribution services agreement with McKesson Corporation (NYSE: MCK), one of the largest pharmaceutical distributors and healthcare services companies in North America. Under the agreement, McKesson will serve as an authorized distributor of record for LYMPHIR (denileukin diftitox-cxdl), a novel immunoth",
        "pubDate": "2025-10-20T12:37:00Z",
        "displayTime": "2025-10-20T12:37:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/92b6ee873ab0a518804912f9102afc89",
          "originalWidth": 357,
          "originalHeight": 400,
          "caption": "Citius Oncology logo (PRNewsfoto/Citius Oncology, Inc.)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/y2XksplMkfxHdAxO6NcS8A--~B/aD00MDA7dz0zNTc7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/92b6ee873ab0a518804912f9102afc89.cf.webp",
              "width": 357,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fkV8DMk.3tbp0nLHFILvAw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/92b6ee873ab0a518804912f9102afc89.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/citius-oncology-signs-u-distribution-123700294.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/citius-oncology-signs-u-distribution-123700294.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MCK"
            },
            {
              "symbol": "CTOR"
            },
            {
              "symbol": "CTXR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]